U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370532) titled 'Etoricoxib in Patients With Parkinsonian Disease' on Jan. 17.
Brief Summary: Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Study Start Date: June 30, 2026
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: L-dopa
Levodopa...